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Abstract Metabolic dysfunction underlies several chronic diseases, many of which are
exacerbated by obesity. Dietary interventions can reverse metabolic declines and slow aging,
although compliance issues remain paramount. 17a-estradiol treatment improves metabolic
parameters and slows aging in male mice. The mechanisms by which 17a-estradiol elicits these
benefits remain unresolved. Herein, we show that 17a-estradiol elicits similar genomic binding and
transcriptional activation through estrogen receptor a (ERa) to that of 17b-estradiol. In addition,
we show that the ablation of ERa completely attenuates the beneficial metabolic effects of 17a-E2
in male mice. Our findings suggest that 17a-E2 may act through the liver and hypothalamus to
improve metabolic parameters in male mice. Lastly, we also determined that 17a-E2 improves
metabolic parameters in male rats, thereby proving that the beneficial effects of 17a-E2 are not
limited to mice. Collectively, these studies suggest ERa may be a drug target for mitigating chronic
diseases in male mammals.
Introduction
Aging is the leading risk factor for most chronic diseases, many of which are associated with declines
in metabolic homeostasis (López-Otı́n et al., 2013). Metabolic detriments associated with advancing
age are further exacerbated by obesity (Villareal et al., 2005; Waters et al., 2013), which has risen
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substantially in the older population (>65 years) over the past several decades (Flegal et al., 2010;
Flegal et al., 2016). Moreover, obesity in mid-life has been shown to accelerate aging mechanisms
and induce phenotypes more commonly observed in older mammals (Bischof and Park, 2015;
Horvath et al., 2014; Nevalainen et al., 2017; Yang et al., 2009; Whitmer et al., 2005a;
Whitmer et al., 2005b; Dye et al., 2017). These observations have led many to postulate that obe-
sity may represent a mild progeria syndrome (Salvestrini et al., 2019; Tzanetakou et al., 2012;
Pérez et al., 2016; Tchkonia et al., 2010; Stout et al., 2017a). Although it is well established that
dietary interventions, including calorie restriction, can reverse obesity-related metabolic sequelae,
many of these strategies are not well tolerated in older patients due to concomitant comorbidities
(Villareal et al., 2005; Jensen et al., 2014). Compliance issues across all age groups also remain a
paramount hurdle due to calorie restriction adversely affecting mood, thermoregulation, and muscu-
loskeletal mass (Dirks and Leeuwenburgh, 2006). These adverse health outcomes demonstrate the
need for pharmacological approaches aimed at curtailing metabolic perturbations associated with
obesity and aging.
17a-estradiol (17a-E2) is one of the more recently studied compounds to demonstrate efficacy
for beneficially modulating obesity- and age-related health outcomes. The NIA Interventions Testing
Program (ITP) found that long-term administration of 17a-E2 extends median lifespan of male mice
in a dose-dependent manner (Strong et al., 2016; Harrison et al., 2014). Our group has been
exploring potential mechanisms by which 17a-E2 may improve healthspan and extend lifespan in a
sex-specific manner. We have found that 17a-E2 administration reduces calorie intake and regional
adiposity in combination with significant improvements in a multitude of systemic metabolic parame-
ters in both middle-aged obese and old male mice without inducing deleterious effects (Stout et al.,
2017b; Steyn et al., 2018; Miller, 2020). Other groups have also determined that lifelong adminis-
tration of 17a-E2 beneficially modulates metabolic outcomes, including glucose tolerance, mTORC2
signaling, and hepatic amino acid composition and markers of urea cycling, which were reported to
be dependent upon the presence of endogenous androgens (Garratt et al., 2017; Garratt et al.,
2018). Additionally, multiple lifespan extending compounds, including 17a-E2, exhibit similar modifi-
cations in liver function (Tyshkovskiy et al., 2019). In all, recent studies by several independent labo-
ratories strongly indicate that the lifespan-extending effects of 17a-E2 are at least associated with, if
not dependent on, metabolic improvements.
Despite the mounting evidence demonstrating that 17a-E2 improves numerous health parame-
ters, the signaling mechanism(s) and primary tissues through which 17a-E2 elicits these benefits
remain unknown. Although 17a-E2 is a naturally occurring enantiomer to 17b-estradiol (17b-E2), it
has been postulated that 17a-E2 signals through a novel uncharacterized receptor (Toran-Aller-
and, 2005; Toran-Allerand et al., 2002; Toran-Allerand et al., 2005; Green and Simpkins, 2000)
as opposed to classical estrogen receptors a (ERa) and b (ERb), which is due to 17a-E2 having signif-
icantly reduced binding affinity for ERa and ERb as compared to 17b-E2 (Edwards and McGUIRE,
1980; Korenman, 1969; Littlefield et al., 1990; Anstead et al., 1997). For this reason, 17a-E2 is
often referred to as a non-feminizing estrogen (Green and Simpkins, 2000; Engler-Chiurazzi et al.,
2017; Kaur et al., 2015). A few studies have suggested that a novel but uncharacterized estrogen
receptor, termed ER-X, may mediate 17a-E2 actions in the brain (Toran-Allerand, 2005; Toran-
Allerand et al., 2002; Toran-Allerand et al., 2005; Green and Simpkins, 2000), although more
recent studies supporting this hypothesis are lacking in the literature. Similarly, no reports to date
have directly tested whether the doses of 17a-E2 shown to improve healthspan and lifespan in mice
are mediated through ERa and/or ERb.
There is a multitude of data in the diabetes and metabolism literature demonstrating that ERa is
a regulator of systemic metabolic parameters. Although most of these studies have historically been
performed in female mammals, more recent studies have demonstrated that ERa also plays a critical
role in modulating metabolism in male mammals. For instance, Allard and colleagues recently dem-
onstrated that genomic actions of ERa regulate systemic glucose homeostasis in mice of both sexes
and insulin production and release in males (Allard et al., 2019). Other studies have also determined
that hepatic steatosis and insulin sensitivity, and therefore the control of gluconeogenesis, are regu-
lated through FOXO1 in an ERa-dependent manner in male mice (Yan et al., 2019). Furthermore,
hepatocyte-specific deletion of ERa was sufficient to abrogate similar estrogen-mediated metabolic
benefits (Guillaume et al., 2019; Qiu et al., 2017; Meda et al., 2020). Given that several reports
have linked the administration of 17a-E2 to improvements in metabolic homeostasis, we
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hypothesized that 17a-E2 signals through ERa to modulate hepatic function and systemic metabo-
lism, thereby potentially contributing to the lifespan-extending effects of 17a-E2.
The work outlined in this report sought to determine if ERa is the primary receptor by 17a-E2 sig-
nals and modulates health parameters in mice. We initially determined that 17a-E2 and 17b-E2 elicit
similar genomic actions through ERa. Given that no studies to date have tested the potential role of
ERa in modulating 17a-E2-mediated effects in vivo, we treated obese wild type (WT) and ERa
knockout (ERa KO) littermate mice with 17a-E2 to determine if the ablation of ERa could attenuate
17a-E2-induced benefits on adiposity, metabolic homeostasis, and hepatic function. We found that
the ablation of ERa completely attenuated all beneficial metabolic effects of 17a-E2. Follow-up stud-
ies in male WT rats undergoing hyperinsulinemic-euglycemic clamps revealed that 17a-E2 modulates
hepatic insulin sensitivity following acute exposure. Given the established connection between the
hypothalamus and liver in the modulation of hepatic insulin sensitivity (Könner et al., 2007;
Ruud et al., 2017; Pocai et al., 2005a; Pocai et al., 2005b; Dodd et al., 2018), coupled with our
data demonstrating ERa-dependency of 17a-E2 actions on metabolic parameters, we speculate that
17a-E2 acts through ERa in the liver and/or hypothalamus to improve metabolic homeostasis in
male mammals.
Results
17a-E2 and 17b-E2 similarly modulate genomic binding and
transcriptional activity of ERa
Ligand-mediated ERa dimerization leads to nuclear translocation and transcriptional activity. Previ-
ous work has shown that 17a-E2 and 17b-E2 can bind to ERa with different affinities (Edwards and
McGUIRE, 1980; Korenman, 1969; Littlefield et al., 1990; Anstead et al., 1997), yet potential dif-
ferences in resultant genomic binding and transcriptional activity between the two ligands remains
unexplored. We assessed ERa DNA binding and transcriptional induction following exposure to 17b-
E2 (10 nM) or 17a-E2 (10 nM or 100 nM) in U2OS cells that stably express ERa following doxycycline
induction. We chose to use these cells because they do not endogenously express any form of ERa
or ERb and have been extensively utilized to elucidate the effects of ERa and ERb agonists and
antagonists on gene expression (Monroe et al., 2003; Monroe et al., 2005). ChIP-sequencing
revealed peaks of ERa genomic binding in all conditions, that when compared, are qualitatively simi-
lar across treatments (Figure 1A). Statistically significant differences in ERa binding were deter-
mined by negative binomial regression with a Wald’s pairwise post-hoc comparison (false discovery
rate correction, FDR < 0.05). A total of 21,443 peaks were found to have a significant pairwise post-
hoc comparison between vehicle and 17a-E2 and/or 17b-E2 treated cells. No statistically significant
differences between 17a-E2 and 17b-E2-treated groups were observed. 17a-E2 and 17b-E2 not only
induced ERa binding at the same genomic locations but also to similar magnitudes. Comparing the
levels of increased or decreased ERa binding (as compared to vehicle control) between treatments
demonstrates the consistency of ERa genomic binding regardless of the agonist (Figure 1B,
Supplementary file 1). The degree of increased or decreased ERa binding was highly similar
between 10 nM 17a-E2 and 10 nM 17b-E2, (Pearson’s r = 0.95, p<0.001) and 100 nM 17a-E2 and 10
nM 17b-E2 (Pearson’s r = 0.96, p<0.001). As expected, ERa-binding sites were enriched for estrogen
response elements (ERE), estrogen-related receptor beta (Esrrb), and estrogen-related receptor
alpha (Erra). Other common motifs found within ER elements, including steroidogenic factor-1 (SF1)
(Lin et al., 2007), and motif elements of known interacting partners, including retinoid acid recep-
tor:retinoid X receptor (RAR:RXR) (Lee et al., 1998), were also enriched (Figure 1C). In addition, we
observed enrichment of androgen response elements (ARE) in ERa peaks (Figure 1C). Of particular
relevance, many of the top enriched motifs identified contained the ERE consensus sequence
TTGAC (Supplementary file 2). Following motif enrichment, we performed pairwise differential
motif enrichment across all groups to determine if a specific agonist or agonist concentration caused
a differential enrichment of any motifs, as would be suggestive of differential genomic binding. No
differential motif binding was observed across treatment groups indicating that both 17a-E2 and
17b-E2 cause ERa to bind to the same types of genomic elements (Hypergeometric test,
FDR < 0.05).





































































































































































































































































































Figure 1. 17a-E2 and 17b-E2 elicit similar genomic binding and transcriptional profiles through ERa. (A) Heatmap representing normalized genome-
wide DNA binding by ERa via ChIP sequencing analyses centered according to peak summits for each treatment group and compared to each other
group. (B) Differential binding was identified between vehicle and 17a-E2 or 17b-E2 treatment groups, but no differences were identified between 17a-
E2 and 17b-E2-treated groups (negative binomial regression, followed by Wald test for pairwise comparisons, FDR < 0.05). Fold change in binding
relative to vehicle control was compared between 17a-E2 treatments and 17b-E2. (C) Motif enrichment analysis, filtered for mammalian and non-
overlapping motif groups, showing the top 10 non-redundant enriched sequence motifs across treatment groups (hypergeometric test, FDR < 0.05), (D)
PCA plot of transcriptional profiles by RNA sequencing analyses demonstrating clustering of 17a-E2 and 17b-E2 treatment groups together, opposite
from Vehicle-treated group along the first principle component, and (E) Heatmap representing differentially expressed genes (negative binomial
regression, followed by Wald test for pairwise comparisons, FDR < 0.05) by RNA sequencing analyses (left) and ERa binding patterns within the gene
body ±5 kb flanking regions of these genes via ChIP sequencing (right). Significant differential pairwise expression was observed only between 17a-E2
and 17b-E2 treatment groups and vehicle-treated control. These studies utilized U2OS-ERa cells treated with low dose (10 nM) 17a-E2, high dose (100
nM) 17a-E2, 17b-E2 (10 nM), or vehicle (EtOH). n = 3/group.
Figure 1 continued on next page
Mann et al. eLife 2020;9:e59616. DOI: https://doi.org/10.7554/eLife.59616 4 of 30
Research article Medicine
Next, we examined potential differences in transcriptional responses between treatment groups
using RNA-sequencing. Principle component analysis based on the entire transcriptome revealed
that all samples exposed to either 17a-E2 or 17b-E2 clustered together, whereas vehicle-treated
cells remained distinctly separated from treated cells on the first principle component, which
explains the majority of the variance in transcription (70.6%) (Figure 1D). These data suggest that
treatment vs vehicle is the primary covariate explaining variance in transcriptional profiles, not the
specific agonist. Next, differential expression was assessed between all groups using a negative
binomial regression model with a Wald pairwise post-hoc test. No genes were found to be differen-
tially regulated (FDR < 0.05) between the estrogen treatments. Yet, compared to vehicle-treated
cells, treatment of U2OS cells with either 10 nM or 100 nM 17a-E2 or 10 nM 17b-E2 resulted in
nearly identical gene suppression and activation signatures (Figure 1E, left). Additionally, both 17a-
E2 or 17b-E2 treatment conditions resulted in higher ERa DNA binding affinity to gene bodies of
these differentially expressed transcripts compared to vehicle treatment, and no differences were
observed between 17a-E2 and 17b-E2 conditions (Figure 1E, right) (negative binomial regression
with Wald pairwise post-hoc). These findings led us to postulate that 17a-E2 may be the signaling
through ERa to modulate health parameters in male mice. As such, we subsequently sought to
determine if the ablation of ERa in vivo would mitigate the effects of 17a-E2.
ERa ablation attenuates 17a-E2-mediated benefits on metabolic
parameters in male mice in vivo
To induce obesity and metabolic perturbations in male mice, we administered high-fat diet (HFD) for
several months prior to initiating 17a-E2 treatment. Control mice remained on HFD, whereas 17a-
E2-treated mice were switched to an identical HFD containing 17a-E2. Almost immediately after
17a-E2 treatment began, male WT mice displayed significant reductions in mass (Figure 2A–B) and
adiposity (Figure 2C–D). This is aligned with our previous reports demonstrating that 17a-E2 admin-
istration quickly reduces body mass and adiposity (Stout et al., 2017b; Steyn et al., 2018;
Miller, 2020), which we have linked to hypothalamic regulation of anorexigenic signaling pathways
(Steyn et al., 2018). Indeed, male WT mice in the current study also displayed robust declines in cal-
orie consumption during the first 4 weeks of treatment (Figure 2E). Conversely, all these benefits
were completely abolished in male mice lacking ERa (ERa KO), thereby confirming that 17a-E2
definitively acts through ERa to modulate feeding behaviors, mass, and adiposity in male mice.
Given the close association between adiposity and metabolic homeostasis, coupled with our previ-
ous work demonstrating the ability of 17a-E2 to improve metabolic parameters (Stout et al.,
2017b; Steyn et al., 2018), we also assessed several metabolic variables in these studies. Similar to
the mass and adiposity data described above, male WT mice receiving 17a-E2 displayed significant
improvements in fasting insulin (Figure 3B), HbA1C (Figure 3C), and glucose tolerance (Figure 3D–
E, Figure 3—figure supplement 1), whereas male ERa KO mice receiving 17a-E2 failed to recapitu-
late these findings. Interestingly, despite the masses of the male WT 17a-E2 treatment group being
nearly 15 grams greater than those of the male WT chow-fed controls, glucose tolerance was essen-
tially identical between these groups, thereby indicating that 17a-E2 restores metabolic flexibility in
the presence of obesity in male mice (Figure 3D–E, Figure 3—figure supplement 1). We also evalu-
ated the effects of 17a-E2 on metabolic parameters in female WT and ERa KO mice provided a stan-
dard chow diet. In contrast to the males, we chose not to subject female WT and ERa KO mice to
HFD because female ERa KO mice spontaneously develop obesity due to the ablation of ERa
(Manrique et al., 2012; Vidal et al., 1999). Given that the female ERa KO mice are already in a chal-
lenged state, HFD would further exacerbate mass and adiposity differences between ERa KO and
WT female mice. We found that 17a-E2 failed to elicit improvements in mass, adiposity, calorie con-
sumption, or metabolic parameters in female mice of either genotype (Figure 3—figure supple-
ment 2). The positive effects of 17a-E2 in male mice led us to speculate that the liver may play a key
role in modulating 17a-E2-mediated effects on systemic metabolic homeostasis. Importantly, several
Figure 1 continued
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. 17a-E2 and 17b-E2 elicit similar ERa binding profile.































































Figure 2. ERa is required for 17a-E2 to reduce mass, adiposity, and calorie intake in male mice. (A) Percent change in mass (mean ± SEM, two-way
repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005 between WT HFD and WT HFD+17a), (B) Mass at baseline (week 0; solid)
and week 14 (striped) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), (C) Percent change in fat
mass (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), (D) Fat mass at baseline (week 0; solid) and
week 14 (striped) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), and (E) Average daily calorie
intake per week in WT and ERa KO mice provided 45% HFD (TestDiet 58V8)±17a-E2 (14.4ppm) (mean ± SEM, two-way repeated measures ANOVA with
Figure 2 continued on next page
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studies have implicated hepatic ERa in the regulation of glucose homeostasis, insulin sensitivity, and
crosstalk with hypothalamic neurons that modulate metabolism and feeding behavior (Meda et al.,
2020; Torre et al., 2017; Barros and Gustafsson, 2011).
Figure 2 continued
Holm-Sidak post-hoc; *p<0.05, **p<0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference
















































































































Figure 3. 17a-E2 reverses obesity-related metabolic dysfunction in male WT, but not ERa KO, mice. (A) Fasting glucose (mean ± SEM, two-way
repeated measures ANOVA), (B) Fasting insulin (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), and
(C) glycosylated hemoglobin (HbA1c) at baseline (week 0; solid) and week 14 (striped) in WT and ERa KO mice provided 45% HFD (TestDiet 58V8)±17a-
E2 (14.4 ppm) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; **p<0.005). (D) Glucose tolerance testing (GTT; 1 mg/kg)
(mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05 between WT HFD and WT HFD+17a), and (E) GTT AUC during
week 10 of the study (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; *p<0.05). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were
also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 9–10 (WT HFD), 8–10 (WT
HFD+17a), 9–10 (KO HFD), 8–10 (KO HFD+17a), 12–15 (WT Chow).
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. 17a-E2 reverses obesity-related metabolic dysfunction in male WT, but not ERa KO, mice.
Figure supplement 2. 17a-E2 fails to alter metabolic parameters in WT or ERa KO female mice.
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17a-E2 improves liver disease pathology in an ERa-dependent manner
in male mice
We previously reported that 17a-E2 alters hepatic lipid deposition and DNA damage responses in
male mice through unknown mechanisms (Stout et al., 2017b). In the current study, we sought to
determine if these findings are mediated through ERa. We found that 17a-E2 significantly reduced
liver mass and steatosis in male WT, but not ERa KO mice, as evidenced by reductions in oil-red-O
positivity, fatty acid content, and triglyceride accumulation (Figure 4, Figure 4—figure supplement
1). These observations were accompanied by significant alterations in gene expression associated
with de novo lipogenesis (fatty acid synthase [Fasn]) and b-oxidation (peroxisome proliferator-acti-
vated receptor alpha [Ppara]; sterol regulatory element binding transcription factor 1 [Srebf1]) (Fig-
ure 4—figure supplement 1). These findings are similar to previous reports showing that 17b-E2
acts through ERa to modulate the expression and activity of genes that regulate hepatic lipid
metabolism (Della Torre et al., 2016; Stubbins et al., 2012; Zhang et al., 2013). Interestingly,
despite seeing overall reductions in hepatic fatty acid content with 17a-E2 treatment in male WT
mice (Figure 4C), we also observed elevations in specific fatty acids in these mice as compared to
WT HFD controls. Notably, arachidonic acid (AA, 20:4n6) and docosahexaenoic acid (DHA, 22:6n3),
both of which are precursors for eicosanoid, resolvin, and protectin production (Szefel et al., 2015;
Kohli and Levy, 2009), were found to be increased by 17a-E2 treatment in male WT mice (Fig-
ure 4—figure supplement 2). Our findings are aligned with a previous report by Garratt et al. show-
ing that 17a-E2 increases AA and DHA in liver (Garratt et al., 2018). None of the 17a-E2-mediated
changes in fatty acid profiles were observed in male ERa KO mice receiving 17a-E2. In response to
the elevations in AA and DHA with 17a-E2 treatment, we also assessed circulating eicosanoids. We
found that 17a-E2 treatment also mildly altered several circulating eicosanoid concentrations in male
WT mice (Supplementary file 3). Many of these have been linked to changes in inflammatory signal-
ing (Kiss et al., 2010; Gilroy et al., 2016), although the role they are playing in 17a-E2-mediated
effects of on metabolism and/or aging remain unclear.
Due to the association between obesity-related hepatic steatosis and the onset of fibrosis, we
assessed collagen deposition by trichrome staining and found that 17a-E2 reduced this in male WT,
but not ERa KO, mice (Figure 5A). We also observed significant suppression of several transcripts
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 Chow
Figure 4. 17a-E2 reverses obesity-related hepatic steatosis in an ERa-dependent manner in male mice. (A) Liver mass (mean ± SEM, two-way ANOVA
with Holm-Sidak post-hoc; *p<0.05), (B) Representative liver oil-red-O staining, (C) Liver fatty acids (mean ± SEM, two-way ANOVA with Holm-Sidak
post-hoc; **p<0.005), and (D) Liver triglycerides in WT and ERa KO mice provided 45% HFD (TestDiet 58V8)±17a-E2 (14.4ppm) for 14 weeks
(mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; **p<0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a
normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 4–10 (WT HFD), 4–9 (WT HFD+17a), 4–9 (KO
HFD), 4–10 (KO HFD+17a), 4–15 (WT Chow).
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. 17a-E2 alters markers of lipid and glucose homeostasis predominantly through ERa in male mice.
Figure supplement 2. 17a-E2 alters the hepatic fatty acid profile in male WT, but not ERa KO, mice.
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(Col1a1) (Hayashi et al., 2014; Lua et al., 2016), cyclin-dependent kinase inhibitor 1A (Cdkn1a)
(Crary and Albrecht, 1998; Yang et al., 2020), matrix metallopeptidase 1 (Mmp1)
(Lichtinghagen et al., 2003), matrix metallopeptidase 12 (Mmp12) (Madala et al., 2010), monocyte
chemoattractant protein 1 (Ccl2) (Glass et al., 2018; Baeck et al., 2012), C-X-C motif chemokine
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Figure 5. 17a-E2 reverses obesity-related liver fibrosis and insulin resistance in an ERa-dependent manner in male mice. (A) Representative liver
Masson’s trichrome staining for collagen and (B) Liver transcriptional markers of fibrosis in WT and ERa KO mice provided 45% HFD (TestDiet 58V8)±
17a-E2 (14.4ppm) for 14 weeks (box plots depict total range of fold changes in gene expression with mean shown as a horizontal black line, Benjamini–
Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005). (C) Schematic of in vivo insulin stimulation
(2mU/g) in fasting mice, (D) Representative liver immunoblots, and (E) Quantification of phospho/total (p/t) AKT (pS473) and FOXO1 (pS256) in WT and
ERa KO mice provided 60% HFD (TestDiet 58Y1)±17a-E2 (14.4ppm) for 12 weeks (mean ± SEM, Benjamini–Hochberg multiple testing correction, two-
way ANOVA with Holm-Sidak post-hoc; **p<0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight
reference group and the corresponding means are depicted as dashed gray lines. n = 7–10 (WT HFD), 8–9 (WT HFD+17a), 7–10 (KO HFD), 10 (KO HFD
+17a), 7–11 (WT Chow).
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TNF receptor superfamily member 1A (Tnfrsf1a) (Grattagliano et al., 2019; Figure 5B). Transcripts
shown to be predicative of hepatic insulin resistance (follistatin [Fst], inhibin subunit beta E [Inhbe],
insulin receptor substrate 2 [Irs2]) (Tao et al., 2018; Parks et al., 2015) and gluconeogenic plasticity
(phosphoenolpyruvate carboxykinase 1 [Pck1], pyruvate kinase [Pkm]) (Xiong et al., 2011) were also
beneficially modulated by 17a-E2 in male WT mice (Figure 4—figure supplement 1). To confirm
that 17a-E2 improves hepatic insulin sensitivity, we also evaluated phosphorylation status of AKT
and FOXO1 in livers from male WT and ERa KO mice following the administration of an insulin bolus
(Figure 5C). We found dramatic improvements in phosphorylated AKT (pS473) and FOXO1 (pS256)
in male WT mice treated with 17a-E2 (Figure 5D–E), whereas these benefits were not observed in
male ERa KO mice. Our findings are aligned with previous reports demonstrating that hepatic ERa
plays a critical role in regulating insulin sensitivity in the liver of male mice (Yan et al., 2019;
Guillaume et al., 2019; Qiu et al., 2017; Zhu et al., 2014). Collectively, these findings suggest that
the liver is highly responsive to 17a-E2 and that hepatic ERa is likely the signaling mechanism by
which 17a-E2 prevents and/or reverses steatosis, fibrosis, and insulin resistance.
Despite our findings demonstrating that 17a-E2 reduces calorie intake and improves liver disease
parameters in male mice in an ERa-dependent manner, it has historically been unclear if the benefits
attributed to 17a-E2 occur primarily due to long-term reductions in calorie intake. Moreover, it
remains unclear if 17a-E2 acts in a tissue-specific manner and if these observations would also occur
in other mammalian species. To address these questions, we subsequently evaluated the effects of
acute 17a-E2 administration during hyperinsulinemic-euglycemic clamps in male WT outbred rats.
These experiments allowed us to evaluate tissue-specific insulin-sensitivity following acute 17a-E2
exposure, thereby circumventing long-term effects of the compound including reductions in calorie
intake.
Acute 17a-E2 administration improves hepatic insulin sensitivity in male
rats
The hyperinsulinemic-euglycemic clamp is the gold-standard for assessing insulin action in vivo
(Ayala et al., 2010). Animals are fasted overnight prior to receiving a constant infusion of insulin and
a variable infusion of [3-3H] glucose to maintain a euglycemia throughout the clamping period. Blood
samples are frequently obtained to assess glucose concentration and adjust glucose infusion rates
(GIRs) to maintain euglycemia, thereby allowing the calculation of insulin sensitivity to be done. Our
first set of experiments in male rats sought to determine if acute peripheral infusions of 17a-E2 mod-
ulates metabolic parameters during hyperinsulinemic-euglycemic clamps (Figure 6A). We found that
acute peripheral administration of 17a-E2 significantly increased systemic insulin responsiveness as
compared to vehicle controls, which is indicated by increased GIRs (Figure 6B). These studies also
determined that peripheral 17a-E2 administration robustly suppressed hepatic gluconeogenesis as
compared to vehicle controls (Ra; Figure 6C–D), whereas glucose disposal rates (Rd; Figure 6E)
were essentially identical between groups under clamped conditions. These data indicate that 17a-
E2 beneficially modulates metabolic parameters independent of reductions in calorie intake and adi-
posity. Furthermore, these findings strongly suggest that the liver is a primary site where 17a-E2
acts to improve metabolic homeostasis due to gluconeogenesis being tightly controlled by hormonal
actions on hepatocytes (Zhang et al., 2018). However, it also well established that the hypothalamus
can directly modulate gluconeogenesis in the liver through hepatic innervation (Timper and Brüning,
2017); therefore, we sought to determine if acute intracerebroventricular (ICV) delivery of 17a-E2
(Figure 6F) could modulate metabolic parameters similarly to that observed during peripheral 17a-
E2 administration. Interestingly, we found that central administration of 17a-E2 essentially phe-
nocopied the effects of peripheral 17a-E2 infusion with regard to GIRs and suppression of hepatic
gluconeogenesis (Figure 6G–I). These findings suggest that 17a-E2 likely acts through hypothalamic
neurons to regulate hepatic gluconeogenesis. Indeed, agouti-related peptide/neuropeptide Y
(AgRP/NPY) and pro-opiomelanocortin (Pomc) neurons are known to regulate hepatic glucose pro-
duction (Könner et al., 2007; Ruud et al., 2017; Pocai et al., 2005a; Pocai et al., 2005b;
Dodd et al., 2018) and both neuronal populations express ERa (Smith et al., 2013; Skinner and
Herbison, 1997; Xu et al., 2011; Acosta-Martinez et al., 2007; Stincic et al., 2018; Kelly and Røn-
nekleiv, 2015; Smith et al., 2014). Collectively, the hyperinsulinemic-euglycemic clamp studies
revealed that 17a-E2 definitively modulates metabolic homeostasis in an acute manner and suggests
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that the liver and hypothalamus are two primary sites of action for the regulation of metabolic
parameters by 17a-E2.
Discussion
17a-E2 has recently been found to increase median lifespan in male mice through uncharacterized
mechanisms (Strong et al., 2016; Harrison et al., 2014). We and others have shown that metabolic
improvements by 17a-E2 may underlie the lifespan extending effects. In these studies, we sought to
determine the role of ERa in 17a-E2-mediated transcriptional effects in vitro and metabolic effects
in vivo. Although previous studies have shown that 17a-E2 has limited binding affinity for ERa, it
remains unclear if 17a-E2 can induce transcriptional and physiological alterations in this manner.
Given the close association between metabolic improvements and ERa activity, we hypothesized
that 17a-E2 signals through ERa to elicit beneficial health outcomes. In these studies, we utilized
U2OS cells stably expressing ERa and ERa global knockout mice to assess the involvement of this
receptor in mediating 17a-E2 effects. Results from these studies demonstrate that ERa plays a piv-
otal role in 17a-E2-mediated effects on genomic activity and metabolism. Moreover, these data sug-
gest that ERa may be a target for the treatment of aging and chronic diseases in males.
Given the similarities between the metabolic benefits observed in vivo with 17a-E2 treatment and
the established body of literature linking ERa activity to systemic metabolic regulation (Barros and
Gustafsson, 2011), we utilized a well-established cell line model to globally assess the ERa cistrome
and transcriptome following 17a-E2 and 17b-E2 treatment. We found that, regardless of dose, 17a-
E2 and 17b-E2 elicited the same pattern of ERa genomic binding loci and these loci shared the
same DNA motif enrichments. Additionally, activation and suppression of gene expression were sim-
ilar with both 17a-E2 and 17b-E2 exposure and were independent of dosage. This provides strong
evidence that 17a-E2 is signaling through ERa to elicit beneficial outcomes, which is contrary to
Figure 6. Acute delivery of 17a-E2 improves hepatic insulin sensitivity. (A) Schematic of peripheral 17a-E2 infusions (or vehicle) during hyperinsulinemic-
euglycemic clamps, (B) glucose infusion rates (GIR) (mean ± SEM, unpaired Student’s t-test; **p<0.005), (C) rate of glucose appearance (Ra; hepatic
glucose production) (mean ± SEM, unpaired Student’s t-test on Clamp; **p<0.005), (D) % suppression of hepatic glucose production (mean ± SEM,
unpaired Student’s t-test; **p<0.005), and (E) rate of glucose disappearance (Rd; peripheral glucose disposal) in 6 month old, male, FBN-F1 hybrid rats
(mean ± SEM, unpaired Student’s t-test on Clamp). (F) Schematic of ICV (central) 17a-E2 infusions (or vehicle) during hyperinsulinemic-euglycemic
clamps, (G) GIR (mean ± SEM, unpaired Student’s t-test; *p<0.05), (H) Ra (mean ± SEM, unpaired Student’s t-test on Clamp; **p<0.005), (I) %
suppression glucose production (mean ± SEM, unpaired Student’s t-test; *p<0.05), and (J) Rd in 6-month-old, male, FBN-F1 hybrid rats (mean ± SEM,
unpaired Student’s t-test on Clamp). n = 5–9 (Veh.), 7–8 (17a).
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what other reports have suggested (Harrison et al., 2014; Garratt et al., 2017; Garratt et al.,
2018; Toran-Allerand et al., 2002; Toran-Allerand et al., 2005; Toran-Allerand, 2005). Toran-
Allerand et al. reported that 17a-E2 signals through a novel receptor in the brain, which they termed
ER-X (Toran-Allerand et al., 2002; Toran-Allerand, 2005). Although our findings appear to dispute
this notion, several reports have shown that ERa exists and functions as multiple alternatively spliced
variants (Flouriot et al., 1998; Wang et al., 2005; Taylor et al., 2010; Zhang et al., 2016;
Lin et al., 2013). Therefore, we speculate that ER-X may have been a truncated,
alternatively spliced, form of ERa, which nonetheless causes the same genomic and transcriptomic
effects. These findings led us to investigate how ERa may modulate 17a-E2-induced benefits in vivo
using ERa global KO mice.
In alignment with our previous reports (Stout et al., 2017b; Steyn et al., 2018), 17a-E2 reduced
calorie intake, body mass, adiposity, and obesity-related metabolic perturbations in male WT mice.
Conversely, 17a-E2 failed to elicit these beneficial effects in ERa KO mice, further supporting our
hypothesis that ERa is the receptor by which 17a-E2 signals to induce beneficial metabolic out-
comes. These observations are similar to how ERa is known to mediate the actions of endogenous
estrogens on metabolic parameters in females (Barros and Gustafsson, 2011). In particular, 17b-E2
acts through ERa to regulate systemic insulin sensitivity, lipid distribution, thermogenesis, and hypo-
thalamic anorexigenic pathways (Barros and Gustafsson, 2011; Stincic et al., 2018; López and
Tena-Sempere, 2015). The loss of endogenous estrogen action due to menopause in humans or
ovariectomy (OVX) in rodents eliminates these beneficial effects and elicits metabolic perturbations
(Stefanska et al., 2015). Moreover, OVX following sexual maturation has also been shown to reduce
lifespan in female mice (Benedusi et al., 2015), indicating that endogenous estrogens regulate life-
span in females; which we surmise is at least partially mediated through ERa.
In the current study, 17a-E2 failed to induce beneficial metabolic effects in female mice of either
genotype, which we postulate is due to endogenous 17b-E2 saturating ERa in female WT mice,
thereby limiting the potential benefits of 17a-E2 treatment. This interpretation is supported by our
recent report showing that OVX renders WT female mice responsive to the beneficial effects of 17a-
E2 on adiposity and bone mass (Mann et al., 2020), both of which are regulated by ERa activity
(Heine et al., 2000; Khosla and Monroe, 2018). In males, very few studies have evaluated the role
of ERa in metabolism, although a few recent reports have suggested that ERa plays tissue-specific
roles, particularly in the liver, by regulating glucoregulatory pathways (Allard et al., 2019;
Yan et al., 2019; Guillaume et al., 2019; Qiu et al., 2017; Meda et al., 2020; Zhu et al., 2014).
These studies, coupled with our current findings, led us to speculate that 17a-E2 may be signaling
through ERa in the liver to reverse metabolic disease and potentially extend healthspan and/or life-
span in males.
The liver is a major regulator of systemic metabolic homeostasis. Obesity and advancing age
often promote a variety of liver conditions, including steatosis, fibrosis, and insulin resistance; all of
which are associated with hallmarks of aging (Hunt et al., 2019), including cellular senescence
(Ogrodnik et al., 2017), epigenetic alterations (Horvath et al., 2014), and dysregulated nutrient-
sensing (López-Otı́n et al., 2013). We have previously shown that 17a-E2 can reduce hepatic steato-
sis, hepatic insulin resistance, and hepatocyte DNA damage through unknown mechanisms
(Stout et al., 2017b). In the present study, we sought to determine if these findings are mediated
through ERa. We found that 17a-E2 dramatically reduced liver mass and lipid content. As expected,
these observations were not seen in ERa KO mice, providing further support for the hypothesis that
17a-E2 regulates systemic metabolic parameters through ERa. Interestingly, our findings suggest
that 17a-E2 suppresses de novo lipogenesis and increases b-oxidation, predominantly in an ERa-
dependent manner. This is aligned with previous reports showing that 17b-E2 can modulate hepatic
lipid dynamics through both genomic and non-genomic actions (Pedram et al., 2016), leading to
altered expression of rate limiting enzymes that control de novo lipogenesis (Zhang et al., 2013)
and b-oxidation (Camporez et al., 2013). Reports have also shown that 17b-E2 can increase triglyc-
eride export, thereby decreasing hepatic lipid deposition (Zhu et al., 2013). Although we did not
directly assess cholesterol profiles in these studies, we speculate that 17a-E2 may partially reduce
hepatic steatosis by increasing VLDL synthesis and/or triglyceride incorporation into VLDL. Addi-
tional studies will be needed to confirm how 17a-E2 alters hepatic lipoprotein dynamics.
Hepatic steatosis promotes liver fibrosis, which exacerbates hepatic insulin resistance (Kim et al.,
2015). Endogenous estrogens and hormone replacement therapies in post-menopausal women
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have been shown to serve a protective role on liver function (Stubbins et al., 2012;
Camporez et al., 2013; Zhu et al., 2013; Rossi et al., 2004; Brussaard et al., 1997). Additionally,
male humans are at a higher risk of developing hepatic steatosis and fibrosis as compared to age-
matched females (Guy and Peters, 2013; GBD 2017 Cirrhosis Collaborators and Collaborators,
2020). In addition to reducing hepatic lipid deposition in male WT mice in the current studies, 17a-
E2 also dramatically suppressed transcriptional and histological markers of hepatic fibrosis in an
ERa-dependent manner. We also determined that 17a-E2 improved hepatic insulin sensitivity in
male WT, but not ERa KO, mice. Several transcriptional markers associated with hepatic insulin resis-
tance were suppressed in male WT mice receiving 17a-E2, whereas this suppression was almost
entirely absent in ERa KO mice. Subsequent studies employing insulin stimulation prior to euthanasia
also revealed that 17a-E2 robustly increased liver AKT and FOXO1 phosphorylation in male WT
mice, indicating a reversal of obesity-related hepatic insulin resistance and increased control of glu-
coneogenesis. These findings clearly demonstrate that 17a-E2 modulates hepatic insulin sensitivity
in an ERa-dependent manner. These observations are aligned with previous reports showing that
17b-E2 acts through ERa to improve glucoregulation (Meda et al., 2020; Zhu et al., 2013). This pro-
vides further support that 17a-E2 is eliciting metabolic improvements through ERa that are specific
to the liver. Therefore, hepatic ERa may be a promising target for the development of therapeutics
to alleviate metabolic disease in males. Future studies utilizing cell-type-specific ablation of ERa in
the liver will be needed to unravel these possibilities.
Despite the robust effects of 17a-E2 on liver function, it remained unclear if 17a-E2 directly mod-
ulates hepatic insulin sensitivity or if these benefits were a secondary response to prolonged reduc-
tions in calorie intake, adiposity, and lipid redistribution. To test this, we performed
hyperinsulinemic-euglycemic clamps, in conjunction with acute infusions of 17a-E2 in male WT rats.
We found that peripheral infusions of 17a-E2 improved hepatic insulin sensitivity almost immedi-
ately, as evidenced by a greater suppression of hepatic glucose production in rats receiving 17a-E2
as compared to vehicle controls. Additionally, we did not observe improvements in glucose disposal,
thereby indicating that 17a-E2 does not acutely increase systemic insulin-stimulated glucose uptake.
This observation is aligned with recent literature demonstrating limited involvement of ERa in skele-
tal muscle insulin sensitivity (Iñigo et al., 2020). These data indicate that 17a-E2 primarily alters sys-
temic metabolic homeostasis through the modulation of hepatic gluconeogenesis, which is known to
account for 76–87% of glucose production in the body (Cherrington et al., 1994). Although these
studies are suggestive of direct actions in the liver, 17a-E2 also has the ability to cross the blood
brain barrier and elicit responses in the hypothalamus (Steyn et al., 2018). Given that the hypothala-
mus can regulate hepatic glucose production (Könner et al., 2007; Ruud et al., 2017; Pocai et al.,
2005a; Pocai et al., 2005b; Dodd et al., 2018; Timper and Brüning, 2017), we also evaluated sys-
temic insulin sensitivity following central administration of 17a-E2. These experiments essentially
phenocopied the results of the peripheral 17a-E2 infusions, suggesting that the suppression of
hepatic gluconeogenesis by 17a-E2 is at least partially mediated by the hypothalamus. A multitude
of studies have shown that the arcuate nucleus (ARC) of the hypothalamus plays a critical role in the
regulation of hepatic gluconeogenesis through autonomic regulation and vagus nerve activity
(Ruud et al., 2017; Pocai et al., 2005a; Zhang et al., 2018; Brandt et al., 2018). Multiple neuronal
populations within the ARC are known to be involved in the regulation of hepatic glucose produc-
tion, including Pomc (Dodd et al., 2018) and AgRP/NPY (Könner et al., 2007; Ruud et al., 2017;
Pocai et al., 2005a; Pocai et al., 2005b). Similarly, we have previously shown that the effects of
17a-E2 on calorie intake and adiposity are dependent upon functional Pomc neurons, thereby pro-
viding evidence that 17a-E2 can act through the hypothalamus to mediate systemic metabolic
parameters (Steyn et al., 2018). However, in the absence of functional Pomc neurons, 17a-E2 was
still able to reduce fasting glucose and insulin, suggesting that 17a-E2 modulates peripheral metab-
olism through multiple mechanisms, which may include alternative neuronal populations. Given that
both Pomc (Xu et al., 2011) and AgRP/NPY (Smith et al., 2013; Skinner and Herbison, 1997;
Acosta-Martinez et al., 2007; Stincic et al., 2018; Kelly and Rønnekleiv, 2015; Smith et al., 2014;
Sar et al., 1990) neurons express ERa, regulate systemic metabolic parameters, and modulate feed-
ing circuitry in a coordinated counter-regulatory fashion, it remains unclear whether 17a-E2 is alter-
ing hepatic and systemic metabolic parameters through Pomc and/or AgRP/NPY neurons.
Interestingly, a recent report from Debarba et al. demonstrated that 17a-E2 increased hypothalamic
ERa expression in the ARC (Debarba, 2020), which further suggests that 17a-E2 signals through
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ERa in the hypothalamus. Future studies utilizing hypothalamic cell-type-specific ERa KO models will
be needed to disentangle which populations of neurons are required for 17a-E2 to control food
intake, peripheral glucose homeostasis, and insulin sensitivity.
Collectively, our findings strongly suggest that 17a-E2 acts through ERa in the liver and/or hypo-
thalamus to modulate metabolic parameters. However, our findings are in contrast to other reports
suggesting that 17a-E2 elicits health benefits by modulating androgen metabolism (Garratt et al.,
2017; Garratt et al., 2018; Garratt and Stout, 2018). Garratt et al. reported that responsiveness to
17a-E2 was significantly attenuated in castrated male mice (Garratt et al., 2018), which the authors
proposed may indicate 17a-E2 acts as a 5a-reductase inhibitor (Schriefers et al., 1991) to prevent
the conversion of testosterone into dihydrotestosterone (DHT). 17a-E2 is known to be a mild 5a-
reductase inhibitor that is prescribed as a topical treatment for androgenetic alopecia (Orfanos and
Vogels, 1980). 5a-Reductase inhibition could conceivably elicit beneficial metabolic effects by either
reducing the concentration of DHT, which has been shown to decrease adiposity (Movérare-
Skrtic et al., 2006; Bolduc et al., 2004), or by promoting greater aromatization of testosterone to
17b-E2 (Veldhuis et al., 2009), which has been linked to improvements in metabolic parameters
(Rubinow, 2017). If true, this would imply that the benefits of 17a-E2 are occurring in an indirect
manner. However, the dose of 17a-E2 used in the vast majority of these studies, does not induce
dramatic feminization of the sex hormone profiles in male mice (Stout et al., 2017b), which leads us
to speculate that 17a-E2 is acting in a direct manner through ERa rather than indirectly through
androgen modulation. Furthermore, studies in male rodents (Livingstone et al., 2015;
Dowman et al., 2013) and humans Wei et al., 2019 demonstrate that 5a-reductase inhibition or
deficiency increases insulin resistance and hepatic steatosis and fibrosis, which are contradictory to
the effects of 17a-E2 treatment in all of our studies utilizing male mice (Stout et al., 2017b;
Steyn et al., 2018; Miller, 2020; Sidhom et al., 2020). Despite these contrasting observations, the
studies by Garratt et al. do provide important insights into the interconnected and underappreciated
relationship between androgen- and estrogen-signaling pathways and their roles in metabolism and
aging. For instance, several recent reports have demonstrated interactions between the androgen
receptor (AR) and ERa (D’Amato et al., 2016; Panet-Raymond et al., 2000; Peters et al., 2009),
which suggests that modulation of one may affect function of the other. Additional factors to con-
sider when comparing and contrasting our studies from those of Garratt et al. are differences in the
length of study, age, and obesity status of the mice, and counterregulatory and/or compensatory
effects of castration. Notably, it is plausible that 17a-E2 could be inducing metabolic benefits and
lifespan-extending effects through several distinct mechanisms, including direct actions through
ERa, suppression of DHT production, and/or aromatization of testosterone. Future studies will be
needed to discern the potentially interdependent nature of 17a-E2 actions on ERa and androgen
metabolism in metabolic improvement and lifespan extension.
There are a few notable caveats to our studies. First, we utilized constitutive global ERa KO mice,
which have been shown to display varying degrees of compensatory ERb activity due to the absence
of ERa during development (Sánchez-Criado et al., 2012; Rosenfeld et al., 1998). However, if com-
pensatory ERb expression was playing a role in our study, we likely would not see a complete attenu-
ation of 17a-E2-mediated effects. As such, the results of our studies clearly indicate that ERa is the
primary receptor by which 17a-E2 signals. Another potential concern of the model is that ERa KO
mice are known to have elevated endogenous testosterone levels (Gould et al., 2007), although the
studies by Garratt et al. would suggest that higher testosterone levels could potentially render the
male mice more responsive to 17a-E2, whereas we observed the opposite. Future studies utilizing
inducible Cre models to knockdown ERa post-sexual development may be considered if it is deter-
mined that Cre induction and subsequent ERa ablation is consistent throughout multiple organ sys-
tems, which has been shown to be inconsistent in other reports (Murray et al., 2012). Despite these
minor concerns related to the model, the use of the constitutive global ERa KO was undoubtedly
the best option for these studies. However, it must also be noted that female mice present a greater
phenotypic response than males to the ablation of ERa, thereby exacerbating obesity and metabolic
dysfunction which makes comparisons to female WT mice as well as their male littermates problem-
atic (Manrique et al., 2012; Vidal et al., 1999). For this reason, we chose not to provide HFD to
female mice in these studies. Regardless, 17a-E2 still failed to elicit beneficial responses in female
mice of either genotype (WT or ERa KO), which is aligned with previous reports demonstrating a
lack of effect of 17a-E2 in intact females (Garratt et al., 2017; Garratt et al., 2018). We also
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recently reported that OVX renders female mice responsive to several of the benefits conferred by
17a-E2 treatment in male mice (Mann et al., 2020). These observations, coupled with the genomic
data presented herein, support the hypothesis that endogenous 17b-E2 actions on ERa diminishes
potential benefits of 17a-E2 in intact female mice. However, future studies will be needed to defini-
tively determine if female mice subjected to diet-induced obesity will display responsiveness to 17a-
E2 once severe metabolic dysfunction has emerged. Lastly, the current studies were relatively short
in duration and it remains unclear if metabolic improvements with 17a-E2 treatment are required for
the lifespan extension effects of the compound. Although several other studies have evaluated the
long-term effects of 17a-E2 (Strong et al., 2016; Harrison et al., 2014; Garratt et al., 2017;
Garratt et al., 2018), a shorter treatment duration was effective for testing our hypothesis in these
studies. Similarly, given the close relationship between metabolic homeostasis, sex hormones, and
longevity (López-Otı́n et al., 2013; Barros and Gustafsson, 2011), we surmise that future studies
evaluating the effects of ERa on male lifespan in the presence or absence of 17a-E2 will be needed.
Although our current report does not provide direct evidence that ERa modulates the lifespan
extending effects of 17a-E2, it does provide insight into the involvement of hepatic and/or hypotha-
lamic ERa on 17a-E2-mediated metabolic effects in male mice.
In summary, the data presented herein are the first to show that 17a-E2 and 17b-E2 induce nearly
identical ERa chromatin association patterns and transcriptional activity. Moreover, we demonstrate
that the metabolic benefits of 17a-E2 in male mice are ERa-dependent. We also provide evidence
that strongly suggests 17a-E2 acts through the liver and hypothalamus to regulate metabolic
homeostasis in male mice. These effects were mirrored by studies in male WT rats receiving 17a-E2,
indicating that 17a-E2 can modulate metabolism almost instantaneously and that these effects are
not limited to a single mammalian species. Future studies will be needed to confirm that 17a-E2 acts
predominantly through ERa in a cell-type-specific manner in the liver and hypothalamus to modulate
systemic metabolic homeostasis. It is also imperative that we determine if ERa exclusively modulates
the lifespan-extending effects of 17a-E2 in male mice. Another potential avenue of investigation that
remains unresolved is whether 17a-E2 acts through ERa in a genomic or non-genomic manner to
modulate health parameters. Potential interactions between androgen and estrogen signaling must
also be considered when evaluating the effects of 17a-E2 on metabolism and lifespan. These studies
will provide additional insight into mechanisms of metabolic improvement and lifespan extension by
17a-E2. Our studies provide critical insight into the molecular mechanisms by which 17a-E2 elicits












ERa (Esr1) KO mice
Cell line
(Homo sapien)










Protein G Dynabeads Applied Biosystems/
Thermofisher Scientific
10003D IP: 30 uL per IP
Chemical compound,
drug
17a-E2 Steraloids, Inc E0870-000
Chemical compound,
drug
Novolin R 100 U/ml Novolin 2mU/g
Other (diet) Chow; TestDiet 58YP TestDiet TestDiet 58YP
Other (diet) HFD; TestDiet 58V8 TestDiet TestDiet 58V8 HFD 45% by kcal
Other (diet) HFD; TestDiet 58Y1 TestDiet TestDiet 58Y1 HFD 60% by kcal
Continued on next page













Free Glycerol Agent Sigma-Aldrich Sigma F6428
Commercial assay
or kit
Triglyceride Reagent Sigma-Aldrich Sigma F6428
Commercial assay
or kit












































































































Software, algorithm SigmaPlot 12.5 Systat Software RRID:SCR_003210 statistical analyses
Software, algorithm ImageJ ImageJ RRID:SCR_003070 histological quantification
Software, algorithm Image Studio LI-COR RRID:SCR_015795 western blot quantification






















Mann et al. eLife 2020;9:e59616. DOI: https://doi.org/10.7554/eLife.59616 16 of 30
Research article Medicine
U2OS cells
U2OS osteosarcoma cells stably expressing flag-tagged ERa (U2OS-ERa) under the control of doxy-
cycline (dox)-inducible promoter (Monroe et al., 2003) were utilized for the studies described here.
U2OS cells were originally purchased from ATTC and were authenticated using IDEXX BioAnalytics
(Westbrook, ME). Cells were also regularly checked for mycoplasma contamination using a PCR-
based mycoplasma detection kit from SouthernBiotech (Birmingham, AL) and were confirmed to be
negative. U2OS-ERa cells were cultured in phenol-free aMEM medium supplemented with 10%
HyCloneTM charcoal/dextran stripped FBS (GE Healthcare Life Sciences, Pittsburgh, PA), 1% antibi-
otic/antimycotic, 5 mg/L blasticidin S, and 500 mg/L zeocin in a humidified 37˚C incubator with 5%
CO2. Cells were plated in 12-well plates in the presence of doxycycline to induce ERa expression.
The following day, cells were treated for 24 hr with 17b-E2 (10 nM) or 17a-E2 (10 nM and 100 nM)
(Steraloids, Newport, RI) in charcoal-stripped FBS-containing media.
ChIP-sequencing
To evaluate patterns of ERa binding agonized by 17a-E2 vs 17b-E2, we performed ChIP-Sequencing.
U2OS-ERa cells were harvested 24 hr post-treatment and chromatin immunoprecipitation was per-
formed as previously described (Reese et al., 2018; Nelson et al., 2006). Briefly, ERa was immuno-
precipitated overnight at 4˚C using 10 mg of Flag antibody (clone M2, Sigma-Aldrich, St. Louis, MO).
Complexes bound to the antibody were captured with protein G Dynabeads (Thermo Fisher Scien-
tific, Waltham, MA), extensively washed, and reverse cross-linked at 65˚C overnight. DNA isolation
was performed by phenol/chloroform extraction and was used for ChIP-sequencing library prepara-
tion. Libraries were sequenced using paired-end 100 bp reads on the Illumina HiSeq 4000
(GSE151039). Reads were aligned to the human genome (hg19, https://genome.ucsc.edu/cgi-bin/
hgGateway) using bowtie2 (Langmead and Salzberg, 2012) and duplicated reads were flagged
with Picard-tools (http://broadinstitute.github.io/picard/). ERa-binding peaks were called using
MACS2 (Zhang et al., 2008) with recommended settings. Peak genomic location, breadth of cover-
age, and peak summit location were determined using MACS2. NarrowPeak files containing peak
information were used to determine differential ERa binding. First, peaks were centralized around
the summit and 250 bp flanking regions were added to the summit location to generate equal 500
bp regions across all experimental groups. Peak files were then used to extract read counts from the
aligned de-duplicated BAM file using samtools (Li et al., 2009), read counts were then normalized
to total library sequencing depth. To determine differential binding, the R package diffbind was uti-
lized (Ross-Innes et al., 2012). Normalized read counts were log2 transformed and normalized
across all experimental groups. Differential binding between treatment groups was determined
using negative binomial regression models utilized in the R package DESeq2, statistical significance
for pairwise comparisons between experimental groups was determined using Wald test. To account
for multiple comparisons, we used Benjamini-Hochberg multiple testing correction (False-discovery
rate, FDR). Motif analysis was performed using HOMER with standard settings to identified motifs.
Peak regions called for each treatment group were analyzed to identify enriched motifs relative to
the entire genome. For pairwise differential motif enrichment or depletion between experimental
groups, we utilized a hypergeometric test with the number of sequences with a motif from each
group and total number of peaks as total sample size. Motifs that appeared in less than five sequen-
ces between both pairwise test groups were removed. Benjamini-Hochberg multiple testing correc-
tion was utilized to control for multiple testing (FDR < 0.05).
RNA-sequencing
U2OS-ERa cells were harvested 24 hr post-treatment and RNA was extracted using Trizol and
DNase cleanup. RNA libraries were prepared with Illumina’s TrueSeq RNA-seq library prep accord-
ing to manufacturer protocol. Libraries were sequenced with 150 bp paired-end reads on the Illu-
mina 4000 platform (Illumina, San Diego, CA) (GSE151039). Sequence quality control was performed
with fastQC, Paired reads were trimmed using trimmomatic, and were aligned to the hg19 genome
using STAR (Dobin et al., 2013). Differential expression was determined using previously described
methods (Hadad et al., 2019). In brief, gene counts were determined with the R package Genomi-
cAlignments ‘summarizeOverlap’ function. Gene counts were then transformed using regularized log
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transformation and normalized relative to library size using the DESeq2 (Love et al., 2014) R pack-
age. Differential expression was determined using negative binomial generalized linear model using
counts ~ treatment model. We performed pairwise differential expression between all experimental
groups using Wald test. All comparisons were corrected for multiple testing using Benjamini-Hoch-
berg multiple testing correction method. Differential expression significance threshold was set to
FDR corrected p<0.05.
Animal study 1
To determine if ERa is the primary receptor by which 17a-E2 signals to elicit metabolic benefits in
vivo, we utilized male global ERa KO and WT littermate mice. Mice were acquired from Dr. Kenneth
Korach (National Institute of Environmental Health Sciences [NIEHS]) and were also bred at OUHSC
by pairing ERa heterozygous KO mice (JAX; strain #026176). Mice were fed a 45% high-fat diet
(HFD) (TestDiet 58V8, 35.5% CHO, 18.3% PRO, 45.7% FAT) from TestDiet (Richmond, IN) for 4
months prior to study initiation to induce obesity and metabolic perturbations. Additionally, age-
matched, male WT, chow-fed mice were maintained on TestDiet 58YP (66.6% CHO, 20.4% PRO,
13.0% FAT) throughout the entire study as a healthy-weight reference group. Mice were individually
housed with ISO cotton pad bedding, cardboard enrichment tubes, and nestlets at 22 ± 0.5˚C on a
12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to food and water
throughout the experimental timeframe. At the conclusion of the fattening period, all mice (age: 6–8
months) receiving HFD were randomized within genotype by age, body mass, fat mass, calorie
intake, fasting glucose, fasting insulin, and glycosylated hemoglobin (HbA1C) into HFD or HFD+17a
(TestDiet 58V8 + 17a-E2, 14.4ppm; Steraloids, Newport, RI) treatment groups for a 14-week inter-
vention. Body mass and calorie intake were assessed daily for the first 4 weeks, followed by body
mass and body composition (EchoMRI, Houston, TX) on a weekly basis. At 10 weeks post-treatment,
mice were fasted for 5–6 hr and fasting glucose, fasting insulin, HbA1C, and glucose tolerance were
assessed. At the conclusion of the study (14 weeks post treatment), mice were euthanized with iso-
flurane in the fasted state (5–6 hr). Blood was collected into EDTA-lined tubes by cardiac puncture,
and plasma was collected and frozen. Tissues were excised, weighed, flash frozen, and stored at
 80˚C unless otherwise noted. Small sections of liver were fixed in 4% paraformaldehyde in prepara-
tion for paraffin- or cryo-embedding for future analyses. All animal procedures were reviewed and
approved by the Institutional Animal Care and Use Committee at OUHSC.
Animal study 2
Although previous studies [Strong et al., 2016; Harrison et al., 2014; Garratt et al., 2017;
Garratt et al., 2018] have demonstrated minimal effects of 17a-E2 in female mice, we thought it
prudent to determine if the ablation of ERa would alter female responsiveness to 17a-E2. Female
WT and ERa KO mice were acquired from Dr. Kenneth Korach (National Institute of Environmental
Health Sciences [NIEHS]). Female mice were maintained on Chow TestDiet 58YP (66.6% CHO, 20.4%
PRO, 13.0% FAT) and were not subject to HFD feeding due to ERa KO female mice naturally dis-
playing an obesity phenotype. Mice were individually housed with ISO cotton pad bedding, card-
board enrichment tubes, and nestlets at 22 ± 0.5˚C on a 12:12 hr light-dark cycle. Unless otherwise
noted, all mice had ad libitum access to food and water throughout the experimental timeframe. At
age 9–11 months, female mice were randomized within genotype by age, body mass, fat mass, calo-
rie intake, fasting glucose, fasting insulin, and glycosylated hemoglobin (HbA1C) into Chow or Chow
+17a-E2 (TestDiet 58YP + 17a-E2,14.4ppm; Steraloids, Newport, RI) treatment groups. The study
was terminated following a 4-week intervention due to a lack of responsiveness to 17a-E2. At the
conclusion of the study, mice were euthanized with isoflurane in the fasted state (5–6 hr). Blood was
collected into EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues
were excised, weighed, flash frozen, and stored at  80˚C. All animal procedures were reviewed and
approved by the Institutional Animal Care and Use Committee at OUHSC.
Animal study 3
To assess insulin sensitivity within the liver, an additional cohort of ERa KO and WT littermate mice
were bred from mice acquired from Jackson Laboratory (JAX; strain #026176), which were gener-
ated from identical founder strains in the laboratory of Dr. Korach at NIEHS. Male ERa KO and WT
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mice were fed a 60% high-fat diet (HFD; TestDiet 58Y1, 20.3% CHO, 18.1% PRO, 61.6% FAT) for 4
months prior to study initiation to induce obesity and metabolic perturbations. Additionally, as was
done in Animal Study 1, age-matched, male WT, chow-fed mice were maintained on TestDiet 58YP
(66.6% CHO, 20.4% PRO, 13.0% FAT) throughout the entire study as a healthy-weight reference
group. Mice were group housed with corncob bedding, cardboard enrichment tubes, and nestlets at
22 ± 0.5˚C on a 12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to
food and water throughout the experimental timeframe. At the conclusion of the fatting period, all
mice (age: 6 months) receiving HFD were randomized within genotype by body mass, fat mass, calo-
rie intake, fasting glucose, and fasting insulin into HFD or HFD+17a (TestDiet 58Y1 + 17a-E2,
14.4ppm; Steraloids, Newport, RI) treatment groups for a 12-week intervention. Prior to being
euthanized, mice were fasted (5–6 hr) and IP injected with insulin (Novolin R 100 U/ml; 2mU/g) to
assess insulin activity and sensitivity in tissue as previously described (Lu et al., 2012). Each mouse
was euthanized with isoflurane 15 min following their insulin injection. Blood was collected into
EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues were excised,
weighed, flash frozen, and stored at  80˚C unless otherwise noted. All animal procedures were
reviewed and approved by the Institutional Animal Care and Use Committee at OUHSC.
Animal study 4
Hyperinsulinemic-euglycemic clamp experiments, the gold-standard for assessing insulin sensitivity,
were performed in male rats to determine if 17a-E2 can acutely modulate insulin sensitivity and glu-
cose homeostasis. FBN-F1 hybrid male rats were acclimated to the animal facilities within the Ein-
stein Nathan Shock Center for 2 weeks prior to undergoing surgeries in preparation for
hyperinsulinemic-euglycemic clamp studies. Rats were fed Purina 5001 (58.0% CHO, 28.5% PRO,
13.5% FAT) and were individually housed with corncob bedding at 22 ± 0.5˚C on a 14:10 hr light-
dark cycle with ad libitum access to food and water. All surgeries were conducted under 2% isoflur-
ane. For clamp studies incorporating central infusions, rats underwent two surgical procedures. First,
stereotactic placement of a steel-guide cannula (Plastics One, Roanoke, VA) reaching the 3rd ventri-
cle was performed. The implant was secured in place with dental cement and animals were treated
with analgesic as needed. Approximately 14 days later, animals underwent a second surgical proce-
dure to place indwelling catheters into the right internal jugular vein and the left carotid artery,
which was also performed for animals undergoing only peripheral clamp studies. Hyperinsulinemic-
euglycemic clamp studies incorporating peripheral 17a-E2 infusions were performed as previously
described (Einstein et al., 2010). For studies employing peripheral infusions of 17a-E2, 17a-E2 was
diluted in sterile saline to a final concentration of 30 ng/ml. Beginning at t = 0 min animals received a
primed-continuous infusion of saline or 30 ng/ml 17a-E2 provided as a 3 mg bolus at a rate of 20 ul/
min over 5 min, followed by a continuous infusion at a rate of 0.06 ml/hr over 235 min (9.4 ng/hr) for
a maintenance dose of 7 mg (total dose 10 mg). Hyperinsulinemic-euglycemic clamp studies with
intracerebroventricular (ICV) infusions were performed as previously described (Huffman et al.,
2016a). 17a-E2 powder (Steraloids, Newport, RI) was dissolved in DMSO at a concentration of 10
mg/ml and stored at  80˚C. For ICV infusions, 17a-E2 was diluted in artificial cerebral spinal fluid
(ACSF) to a final concentration of 2 ng/ml. Beginning at t = 0 min, animals received a primed-continu-
ous ICV infusion of ACSF (Veh.) or 17a-E2 (17a) provided as a 15 ng bolus at a rate of 1 ml/min over
7.5 min, followed by a continuous infusion of 56.5 ng at a rate of 0.08 ml/hr over 6 hr (9.4 ng/hr) and
a total dose of 71.5 ng. All animal procedures were reviewed and approved by the Institutional Ani-
mal Care and Use Committee at the Einstein College of Medicine.
In vivo metabolic analyses in mice
To evaluate the effects of 17a-E2 on metabolic parameters in vivo, we performed several assess-
ments of glucose homeostasis. Unless otherwise noted, all experiments requiring fasting conditions
were performed in the afternoon, 5–6 hr following the removal of food at the beginning of the light-
cycle as outlined elsewhere (Ayala et al., 2010). To ensure fasting conditions, mice were transferred
to clean cages containing ISO cotton padding and clean cardboard enrichment tubes. Non-terminal
blood was collected via tail snip. Fasting glucose was evaluated using a Bayer Breeze 2 Blood Glu-
cose Monitoring System (Bayer Global, Leverkusen, Germany). Fasting insulin was evaluated using a
Mouse Ultrasensitive Insulin ELISA from Alpco (Salem, NH). HbA1c was assessed by A1C-Now
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Monitoring kits (Bayer, Whippany, NJ). Glucose tolerance tests were performed following a 5 hr fast
using an intraperitoneal filtered dextrose injection of 1 g/kg body mass (Huffman et al., 2016b).
Blood glucose was measured immediately pre-injection (time 0) and at 15, 30, 60, 90, and 120 min
post-injection.
Liver histology
To evaluate the effects of 17a-E2 treatment on lipid accumulation and fibrosis, we evaluated fixed
liver tissue. Tissues were fixed in 4% PFA for 24 hr, cryo-embedding samples were transferred to
30% sucrose for 72 hr and embedded in OCT, paraffin-embedding samples were transferred to 1X
PBS for 48 hr, then to 70% ethanol until embedding. Liver oil-red-O and Masson’s trichrome staining
were performed by the Oklahoma Medical Research Foundation Imaging Core Facility using previ-
ously reported methodology (Leonard et al., 2018; Mehlem et al., 2013). Oil-red-O (ORO, Sigma-
Aldrich, St. Louis, MO) and H and E counterstaining were performed on cryo-embedded tissues, and
were imaged within 6 hr of staining. Red lipid stain was blindly quantified from 10 images per animal
using ImageJ software and presented as a lipid to total tissue ratio. Masson’s trichrome staining was
performed on paraffin embedded liver tissue and was used for qualitative purposes. In brief, slides
were stained with Weigert’s Iron Hematoxylin (Sigma-Aldrich, St. Louis, MO), washed, stained with
Biebrich Scarlet-Acid Fusion (Sigma-Aldrich, St. Louis, MO), washed, stained with Phosphomolybdic
Acid-Phosphotunsctic Acid, and then stained with Aniline Blue (Sigma-Aldrich, St. Louis, MO).
Liver triglycerides
We evaluated the effects of 17a-E2 treatment on triglyceride accumulation in the liver. Liver samples
(~100 mg) were homogenized on ice for 60 s in 10X (v/w) Cell Signaling Lysis Buffer (Cell Signaling,
Danvers, MA) with protease and phosphatase inhibitors (Boston BioProducts, Boston, MA). Total
lipid was extracted from the homogenate using the Folch method with a 2:1 chloroform-methanol
mixture (Folch et al., 1957). Lipid was dried down using a nitrogen drier at room temperature, and
resuspended in 100 ml of 3:1:1 tert-butyl alcohol-methanol-Triton X-100 solution. Final triglyceride
concentrations were determined using a spectrophotometric assay with a 4:1 Free Glycerol Agent/
Triglyceride Agent solution (Sigma Triglyceride and Free-Glycerol reagents, St. Louis, MO) as previ-
ously described (Stout et al., 2011).
Liver fatty acids
We evaluated the effects of 17a-E2 on hepatic fatty acid content. Liver samples (~50 mg) were
homogenized and on ice for 60 s in 10X (v/w) Cell Signaling Lysis Buffer (Cell Signaling, Danvers,
MA) with protease and phosphatase inhibitors (Boston BioProducts, Boston, MA). Total lipid was
extracted using a modified Bligh and Dyer method (Bligh and Dyer, 1959) (Sigma-Aldrich, St. Louis,
MO). Of 15:0 and 17:0 internal standards, 50 nmol were added and acid hydrolysis/methanolysis
was done to generate fatty acid methyl esters (FAMEs) (Agbaga et al., 2018). FAMEs were identi-
fied as previously described by GC-MS (Agbaga et al., 2018). A 6890N gas chromatograph with
flame ionization detector (GC-FID) (Agilent Technologies) was used to quantify FAMEs (Yu et al.,
2012). Standards 15:0 and 17:0 were used to compare and determine sample concentrations. Data
is represented as the relative mole percent of each fatty acid.
Plasma eicosanoids
We evaluated the effects of 17a-E2 treatment on circulating eicosanoids (Supplementary file 3).
Plasma eicosanoid analyses were performed by the UCSD Lipidomics Core as described previously
(Quehenberger et al., 2010). Eicosanoids were isolated from plasma, extracted, separated using
liquid chromatography, and analyzed with mass spectrometry (MDS SCIEX 4000 Q Trap; Applied
Biosystems, Foster City, CA) (Quehenberger et al., 2010).
Real-time PCR
To evaluate alterations in gene expression following 17a-E2 treatment, we performed qPCR for
genes related to fibrosis, lipid metabolism, insulin resistance, and glucose metabolism in the liver.
Total RNA was extracted using Trizol (Life Technologies, Carlsbad, CA) and was reverse transcribed
to cDNA with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City,
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CA). Real-time PCR was performed in a QuantStudio 12K Flex Real Time PCR System (Thermofisher
Scientific, Waltham, MA) using TaqMan Gene Expression Master Mix (Applied Biosystems/Thermo-
fisher Scientific, Waltham, MA) and predesigned gene expression assays with FAM probes from Inte-
grated DNA Technologies (Skokie, Illinois). Target gene expression was expressed as 2 DDCT by the
comparative CT method (Livak and Schmittgen, 2001) and normalized to the expression of TATA-
Box Binding Protein (TBP) in liver.
Western blotting
To determine if 17a-E2 altered hepatic insulin sensitivity, we evaluated phosphorylation status of
AKT and FOXO1 following an insulin bolus. Liver was homogenized in RIPA Buffer (Cell Signaling,
Danvers, MA) with protease and phosphatase inhibitors (Boston Bioproducts, Boston, MA). Total
protein was quantified using BCA Protein Assay Reagent Kit (Pierce, Rockford, IL). Proteins were
separated on an Any kD Criterion TGX Stain-Free Protein Gel (Biorad, Hercules, CA) at 75V for 150
min in Running Buffer (Cell Signaling, Danvers, MA) and transferred to a 0.2 mm pore size nitrocellu-
lose membrane, (Biorad, Hercules, CA) at 75V for 90 min on ice. Primary antibodies used were
pS256 FOX01 (Abcam ab131339, 1:1000), FOX01a (Abcam ab52857, 1:1000), pS473 AKT (Abcam
ab81283, 1:3000), pan-AKT (Abcam ab179463, 1:10000), GAPDH (Abcam ab9485, 1:2500). Primary
antibody detection was performed with IRDye 800CW Infrared Rabbit (LI-COR Biotechnology, Lin-
coln, NE) at 1:15,000 concentration. GAPDH was diluted in 5% dry milk (Cell Signaling, Danvers,
MA), all other antibodies were diluted in 5% BSA (Cell Signaling, Danvers, MA). Blot imaging was
done on Odyssey Fc Imaging System (LI-COR Biotechnology, Lincoln, NE) with a two-minute expo-
sure time at 800l, and protein detection and quantification were performed using Image Studio
Software (LI-COR Biotechnology, Lincoln, NE).
Statistical analyses
Results are presented as mean ± SEM unless otherwise stated with p values less than 0.05 consid-
ered to be significant unless otherwise specified. Analyses of differences between groups were per-
formed by two-way ANOVA, two-way repeated measures ANOVA, or Student’s t-test where
appropriate using SigmaPlot 12.5 Software. A Benjamini-Hochberg multiple testing correction was
applied to the F test result to correct for the number of transcripts, proteins, and fatty acids
analyzed.
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. Supplementary file 1. Pairwise statistical comparisons of ERa binding. Negative binomial regres-
sion Wald post-hoc comparison test, FDR < 0.05. n = 3/group.
. Supplementary file 2. ERa binding motif analysis. Motif analysis was performed using HOMER with
standard settings with the significance threshold set to FDR corrected p<0.05. Peak regions called
for each treatment group were analyzed to identify enriched motifs relative to the entire genome.
Hypergeometric test was used to test enrichment. Only motifs with FDR corrected p<0.05 were
reported as significant. For pairwise differential motif enrichment or depletion across experimental
groups, we utilized the hypergeometric test by using the number of sequences with motif from each
group and total number of peaks as total sample size. Motifs that appear in less than five sequences
between both test groups were removed. Benjamini-Hochberg multiple testing correction was uti-
lized to control for false discovery rate (FDR < 0.05).
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. Supplementary file 3. Circulating eicosanoid levels (pmol/ml). 17a-E2 mildly alters the circulating
eicosanoid profile in obese middle-aged male mice. WT mice were provided 45% HFD (TestDiet
58V8)±17a-E2 (14.4ppm) for 14 weeks. Age-matched, male WT, chow-fed (TestDiet 58YP) mice
were also evaluated as a normal-weight reference group. All data are presented as mean ± SEM and
were analyzed by Student’s t-test with the WT Chow group being excluded from statistical compari-
sons. n = 5–7.
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Cowley MA, Ashcroft FM, Brüning JC. 2007. Insulin action in AgRP-expressing neurons is required for
suppression of hepatic glucose production. Cell Metabolism 5:438–449. DOI: https://doi.org/10.1016/j.cmet.
2007.05.004, PMID: 17550779
Koo BK, Um SH, Seo DS, Joo SK, Bae JM, Park JH, Chang MS, Kim JH, Lee J, Jeong WI, Kim W. 2018. Growth
differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver
International 38:695–705. DOI: https://doi.org/10.1111/liv.13587, PMID: 28898507
Korenman SG. 1969. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids
13:163–177. DOI: https://doi.org/10.1016/0039-128X(69)90004-X, PMID: 5773887
Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with bowtie 2. Nature Methods 9:357–359.
DOI: https://doi.org/10.1038/nmeth.1923, PMID: 22388286
Lee SK, Choi HS, Song MR, Lee MO, Lee JW. 1998. Estrogen receptor, a common interaction partner for a
subset of nuclear receptors. Molecular Endocrinology 12:1184–1192. DOI: https://doi.org/10.1210/mend.12.8.
0146, PMID: 9717844
Leonard AK, Loughran EA, Klymenko Y, Liu Y, Kim O, Asem M, McAbee K, Ravosa MJ, Stack MS. 2018. Methods
for the visualization and analysis of extracellular matrix protein structure and degradation. Methods in Cell
Biology 143:79–95. DOI: https://doi.org/10.1016/bs.mcb.2017.08.005, PMID: 29310793
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome
Project Data Processing Subgroup. 2009. The sequence alignment/Map format and SAMtools. Bioinformatics
25:2078–2079. DOI: https://doi.org/10.1093/bioinformatics/btp352, PMID: 19505943
Lichtinghagen R, Bahr MJ, Wehmeier M, MichelsI D, Haberkorn CI, Arndt B, Flemming P, Manns MP, Boeker
KHW. 2003. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and
hepatitis C virus-induced liver cirrhosis. Clinical Science 105:373–382. DOI: https://doi.org/10.1042/
CS20030098
Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A,
George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y,
et al. 2007. Whole-genome cartography of estrogen receptor alpha binding sites. PLOS Genetics 3:e87.
DOI: https://doi.org/10.1371/journal.pgen.0030087, PMID: 17542648
Lin AH, Li RW, Ho EY, Leung GP, Leung SW, Vanhoutte PM, Man RY. 2013. Differential ligand binding affinities
of human estrogen Receptor-a isoforms. PLOS ONE 8:e63199. DOI: https://doi.org/10.1371/journal.pone.
0063199, PMID: 23646196
Littlefield BA, Gurpide E, Markiewicz L, McKinley B, Hochberg RB. 1990. A simple and sensitive microtiter plate
estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of Delta
5adrenal steroids. Endocrinology 127:2757–2762. DOI: https://doi.org/10.1210/endo-127-6-2757, PMID: 224
9627
Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta delta C(T)) Method. Methods 25:402–408. DOI: https://doi.org/10.1006/meth.2001.1262,
PMID: 11846609
Livingstone DE, Barat P, Di Rollo EM, Rees GA, Weldin BA, Rog-Zielinska EA, MacFarlane DP, Walker BR,
Andrew R. 2015. 5a-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic
Steatosis, and liver fibrosis in rodents. Diabetes 64:447–458. DOI: https://doi.org/10.2337/db14-0249,
PMID: 25239636
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Stubbins RE, Holcomb VB, Hong J, Núñez NP. 2012. Estrogen modulates abdominal adiposity and protects
female mice from obesity and impaired glucose tolerance. European Journal of Nutrition 51:861–870.
DOI: https://doi.org/10.1007/s00394-011-0266-4, PMID: 22042005
Szefel J, Kruszewski WJ, Sobczak E. 2015. Factors influencing the eicosanoids synthesis in vivo. BioMed Research
International 2015:690692. DOI: https://doi.org/10.1155/2015/690692, PMID: 25861641
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